BR112021020441A2 - Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra - Google Patents

Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra

Info

Publication number
BR112021020441A2
BR112021020441A2 BR112021020441A BR112021020441A BR112021020441A2 BR 112021020441 A2 BR112021020441 A2 BR 112021020441A2 BR 112021020441 A BR112021020441 A BR 112021020441A BR 112021020441 A BR112021020441 A BR 112021020441A BR 112021020441 A2 BR112021020441 A2 BR 112021020441A2
Authority
BR
Brazil
Prior art keywords
pdgfra
kit
mediated diseases
pyrrolotriazine derivatives
treat
Prior art date
Application number
BR112021020441A
Other languages
English (en)
Inventor
L Kim Joseph
A Dineen Thomas
Timothy Guzi
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of BR112021020441A2 publication Critical patent/BR112021020441A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra. a presente divulgação fornece compostos de fórmula i, sais farmacêuticos dos mesmos e/ou solvatos de qualquer um dos anteriores, que são úteis para tratar doenças e afecções relacionadas a kit mutante e pdgfra e apresentam vantajosamente um perfil não penetrante cerebral para tratar doenças e afecções relacionadas a kit mutante e pdgfra. a presente divulgação também fornece métodos para tratar tumores estromais gastrointestinais e mastocitose sistêmica.
BR112021020441A 2019-04-12 2020-04-08 Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra BR112021020441A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04
PCT/US2020/027177 WO2020210293A1 (en) 2019-04-12 2020-04-08 Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases

Publications (1)

Publication Number Publication Date
BR112021020441A2 true BR112021020441A2 (pt) 2021-12-14

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020441A BR112021020441A2 (pt) 2019-04-12 2020-04-08 Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra

Country Status (19)

Country Link
US (2) US20220153748A1 (pt)
EP (1) EP3953357B1 (pt)
JP (1) JP2022526850A (pt)
KR (1) KR20220025704A (pt)
CN (1) CN113939515A (pt)
AU (1) AU2020272743A1 (pt)
BR (1) BR112021020441A2 (pt)
CA (1) CA3136802A1 (pt)
CL (1) CL2021002656A1 (pt)
CO (1) CO2021015113A2 (pt)
EC (1) ECSP21080096A (pt)
IL (1) IL287168A (pt)
MA (1) MA55604A (pt)
MX (1) MX2021012469A (pt)
PE (1) PE20212331A1 (pt)
SG (1) SG11202111244XA (pt)
TW (1) TW202104231A (pt)
WO (1) WO2020210293A1 (pt)
ZA (1) ZA202108104B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459334B2 (en) 2018-04-16 2022-10-04 Shenzhen Targetrx, Inc. Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
EP4229060A1 (en) * 2020-10-14 2023-08-23 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
US20240166650A1 (en) 2021-03-03 2024-05-23 Blueprint Medicines Corporation Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases
KR20240013720A (ko) 2021-03-10 2024-01-30 블루프린트 메디신즈 코포레이션 키나아제 저해제의 염 및 고체 형태
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
WO2023081923A1 (en) * 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
BR0010482A (pt) 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP2289894A3 (en) 2002-04-23 2011-07-20 Bristol-Myers Squibb Company Pyrrolo-triazine compounds useful as kinase inhibitors
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
PL378296A1 (pl) 2003-02-27 2006-03-20 Palau Pharma S.A. Pochodne pirazolopirydyny
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2006028524A2 (en) 2004-04-29 2006-03-16 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2426448T3 (es) 2006-01-27 2013-10-23 Shanghai Hengrui Pharmaceutical Co. Ltd. Inhibidores de proteína quinasa de pirrolo[3,2-c]piridin-4-ona 2-indolinona
ES2493566T3 (es) 2006-07-07 2014-09-12 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
ES2392003T3 (es) 2007-07-25 2012-12-03 Bristol-Myers Squibb Company Inhibidores de la triazina quinasa
EP2288611B1 (en) 2008-03-20 2013-05-15 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
EP2440051A4 (en) 2009-06-08 2012-12-19 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
WO2011005119A1 (en) 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2013519732A (ja) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RS57542B1 (sr) 2013-10-17 2018-10-31 Blueprint Medicines Corp Kompozicije korisne za lečenje poremećaja povezanih sa kit-om
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
US11040979B2 (en) * 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法

Also Published As

Publication number Publication date
MX2021012469A (es) 2022-01-18
US20220153748A1 (en) 2022-05-19
US20200325141A1 (en) 2020-10-15
IL287168A (en) 2021-12-01
TW202104231A (zh) 2021-02-01
KR20220025704A (ko) 2022-03-03
CO2021015113A2 (es) 2022-02-28
ECSP21080096A (es) 2022-02-25
WO2020210293A1 (en) 2020-10-15
PE20212331A1 (es) 2021-12-14
ZA202108104B (en) 2024-02-28
EP3953357B1 (en) 2024-04-17
EP3953357A1 (en) 2022-02-16
AU2020272743A1 (en) 2021-11-11
SG11202111244XA (en) 2021-11-29
JP2022526850A (ja) 2022-05-26
MA55604A (fr) 2022-02-16
CA3136802A1 (en) 2020-10-15
CN113939515A (zh) 2022-01-14
US10829493B2 (en) 2020-11-10
CL2021002656A1 (es) 2022-08-26

Similar Documents

Publication Publication Date Title
BR112021020441A2 (pt) Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112021016650A2 (pt) Indóis substituídos por n e outros heterociclos para o tratamento de distúrbios cerebrais
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
BR112019001666A2 (pt) n-(fenilsulfonil)benzamidas e compostos relacionados como inibidores de bcl-2
MX2018011792A (es) Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam).
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112022012585A2 (pt) Inibidores de formas mutantes de egfr
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
BR112017006713A2 (pt) inibidor de egfr, e preparação e aplicação do mesmo
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
EA201790992A1 (ru) Иммунорегуляторные агенты
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
BR112016015236A2 (pt) inibidores de serina/treonina quinase
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
EA200801041A1 (ru) Ингибиторы мек и способы их применения
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo